Infectious Diseases in Critical Care Medicine

26. Kieft H, Hoepelman AIM, Knupp CA, et al. Pharmacokinetics of cefepime in patients with the sepsis
    syndrome. J Antimicrob Chemother 1993; 32(suppl B):117–122.


27. Cornwell EE, Belzberg H, Berne TV, et al. Pharmacokinetics of aztreonam in critically ill surgical
    patients. Am J Health-Syst Pharm 1997; 54:537–540.


28. McKindley DS, Boucher BA, Hess MM, et al. Pharmacokinetics of aztreonam and imipenem in
    critically ill patients with pneumonia. Pharmacotherapy 1996; 16:924–931.


29. Boucher BA, Hickerson WL, Kuhl DA, et al. Imipenem pharmacokinetics in patients with burns. Clin
    Pharmacol Ther 1990; 48:130–137.


30. Dailly E, Kergueris MF, Pannier M, et al. Population pharmacokinetics of imipenem in burn patients.
    Fundam Clin Pharmacol 2003; 17:645–650.


31. Belzberg H, Zhu J, Cornwell EE, et al. Imipenem levels are not predictable in the critically ill patient.
    J Tauma 2004; 56:111–117.


32. Fish DN, Teitelbaum I, Abraham E. Pharmacokinetics and pharmacodynamics of imipenem during
    continuous renal replacement therapy in critically ill patients. Antimicrob Agents Chemother 2005;
    49:2421–2428.


33. Hurst M, Lamb HM. Meropenem: a review of its use in patients in intensive care. Drugs 2000; 59:
    653–680.


34. Novelli A, Adembri C, Livi P, et al. Pharmacokinetic evaluation of meropenem and imipenem in
    critically ill patients with sepsis. Clin Pharmacokinet 2005; 44:539–549.


35. Burkhardt O, Kumar V, Katterwe D, et al. Ertapenem in critically ill patients with early-onset
    ventilator-associated pneumonia: pharmacokinetics with special consideration of free-drug concen-
    tration. J Antimicrob Chemother 2007; 59:277–284.


36. Lipman J, Scribante J, Gous AGS, et al. Pharmacokinetic profiles of high-dose intravenous
    ciprofloxacin in severe sepsis. Antimicrob Agents Chemother 1998; 42:2235–2239.


37. Gous A, Lipman J, Scribante J, et al. Fluid shifts have no influence on ciprofloxacin pharmacokinetics
    in intensive care patients with intra-abdominal sepsis. Int J Antimicrob Agents 2005; 26:50–55.


38. Van Zanten ARH, Polderman KH, van Geijlswijk IM, et al. Ciprofloxacin pharmacokinetics in
    critically ill patients: a prospective cohort study. J Crit Care 2008; 23:422–430.


39. Rebuck JA, Fish DN, Abraham E. Pharmacokinetics of intravenous and oral levofloxacin in critically
    ill adults in a medical intensive care unit. Pharmacotherapy 2002; 22:1216–1225.


40. Pea F, Di Qual E, Cusenza A, et al. Pharmacokinetics and pharmacodynamics of intravenous
    levofloxacin in patients with early-onset ventilator-associated pneumonia. Clin Pharmacokinet 2003;
    42:589–598.


41. Benko R, Matuz M, Doro P, et al. Pharmacokinetics and pharmacodynamics of levofloxacin in
    critically ill patients with ventilator-associated pneumonia. Int J Antmicrob Agents 2007; 30:162–168.


42. Gonzalez C, Rubio M, Romero-Vivas J, et al. Bacteremic pneumonia due toStaphylococcus aureus:a
    comparison of disease caused by methicillin-resistant and methicillin-susceptible organisms. Clin
    Infect Dis 1999; 29:1171–1177.


43. Chang FY, Peacock JE Jr, Musher DM, et al.Staphylococcus aureusbacteremia: recurrence and the
    impact of antibiotic treatment in a prospective multicenter study. Medicine 2003; 82:333–339.


44. Wunderink RG, Rello J, Cammarata SK, et al. Linezolid vs vancomycin: analysis of two double-blind
    studies of patients with methicillin-resistantStaphylococcus aureusnosocomial pneumonia. Chest 2003;
    124:1789–1797.


45. Weigelt J, Itani K, Stevens D, et al. Linezolid versus vancomycin in treatment of complicated skin and
    soft tissue infections. Antimicrob Agents Chemother 2005; 49:2260–2266.


46. Whitehouse T, Cepeda JA, Shulman R, et al. Pharmacokinetic studies of linezolid and teicoplanin in
    the critically ill. J Antimicrob Chemother 2005; 55:333–340.


47. Roberts JA, Lipman J. Antibacterial dosing in intensive care: pharmacokinetics, degree of disease and
    pharmacodynamics of sepsis. Clin Pharmacokinet 2006; 45:755–773.


48. Adembri C, Fallani S, Cassetta MI, et al. Linezolid pharmacokinetic/pharmacodynamic profile in
    critically ill septic patients: intermittent versus continuous infusion. Int J Antimicrob Agents 2008;
    31:122–129.


49. Bodey GP, Ketchel SJ, Rodriquez V. A randomized study of carbenicillin plus cefamandole or
    tobramycin in the treatment of febrile episodes in cancer patients. Am J Med 1979; 67:608–616.


50. Buijk SL, Gyssens IC, Mouton JW, et al. Pharmacokinetics of ceftazidime in serum and peritoneal
    exudate during continuous versus intermittent administration to patients with severe intra-
    abdominal infections. J Antimicrob Chemother 2002; 49:121–128.


51. Feld R, Rachlis A, Tuffnell PG, et al. Empiric therapy for infections in patients with granulocytopenia.
    Continuous v interrupted infusion of tobramycin plus cefamandole. Arch Intern Med 1984; 144:1005–1010.


52. Feld R, Valdivieso M, Bodey GP, et al. A comparative trial of sisomicin therapy by intermittent versus
    continuous infusions. Am J Med Sci 1977; 274:179–188.

534 Fry